New Tools to Screen and Diagnose Cervical Cancer in Women
Compares a rapid HPV test with an optical imaging device for cervical changes.
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Maputo, MozambiqueSee the 3 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- Rice Technologies for Cervical Cancer Screening and Diagnosis
- Status
- Recruiting
- People taking part
- 678 people, planned
- Started
- 24 Mar 2021
- Expected to end
- 30 Mar 2028
- Type of study
- Interventional
- Treatments tested
- Multimodal optical imaging
- Record updated
- 10 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 25 to 49 who have a positive cervical cancer screening test and still have their cervix.
- Age
- 25 to 49 years
- Sex
- Women only
- Disease stage
- A positive cervical cancer screening test: abnormal cytology, positive VIA and/or positive HPV test.
Main reasons for not taking part
- Under 25 or over 49 years old
- Had a total hysterectomy (cervix removed)
- Pregnant
- Breastfeeding
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- 25 - 49 year old women
- Women with a positive cervical cancer screening test (abnormal cytology, positive VIA and/or positive HPV test)
- Women with intact cervix
- Women who are not pregnant and with a negative pregnancy test (within 14 days from the date of enrollment) ) and not currently breastfeeding
- Willing and capable of providing informed consent
Who cannot take part
- Women under 25 or over 49 years old
- Women who have undergone a total hysterectomy (with removal of the cervix)
- Women who are pregnant or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 49 years old?
Where in Mozambique
Also in 1 other country, 1 site
- José Macamo General Hospital and Health CenterMaputo, MozambiqueContact: Andrea NevesTaking people
- Maputo Central HospitalMaputo, MozambiqueContact: Ricardina RangeiroTaking people
- Mavalane Hospital and Health CenterMaputo, MozambiqueContact: Arlete MarianoTaking people
About the trial
What the trial wants to find out
The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.
The group in the trial
- Multi-Modal Optical ImagingTreatment being tested
Multi-modal imaging (mobile colposcopy and high resolution imaging) of study participants will be performed during the colposcopy examination. Cervical biopsies will be performed using biopsy forceps per standard protocols.
Treatment: Multimodal optical imaging
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Assessment of New Technologies for the Screening and Diagnosis of Cervical Cancer in Mozambique, A Study to be Conducted in Maputo Central Hospital, Mavalane and Jose Macamo General Hospitals and Mavalane Health Center
- Plain-language title
- New Tools to Screen and Diagnose Cervical Cancer in WomenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05372484, who can take part
- Publications
- Record updated
- 10 August 2026